PMID- 24170533
OWN - NLM
STAT- MEDLINE
DCOM- 20150409
LR  - 20211203
IS  - 2327-6924 (Electronic)
IS  - 2327-6886 (Linking)
VI  - 25
IP  - 11
DP  - 2013 Nov
TI  - Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
PG  - 588-96
LID - 10.1002/2327-6924.12081 [doi]
AB  - PURPOSE: To describe the role of mammalian target of rapamycin (mTOR) inhibition 
      in the treatment of tuberous sclerosis complex (TSC) patients with renal 
      angiomyolipoma in relation to available clinical data and clinical practice 
      guidance for the nurse practitioner (NP). DATA SOURCES: A review of the 
      scientific literature, key clinical congresses, and key clinical trials. 
      CONCLUSIONS: TSC-associated renal angiomyolipomas have a propensity to grow over 
      time and predispose patients to serious and life-threatening consequences. 
      Surgery or invasive interventional therapies may not be the most optimal 
      treatments because of the multiple, bilateral growth pattern of TSC-associated 
      renal angiomyolipomas. Targeted therapies, such as mTOR inhibitors, which have 
      demonstrated efficacy in maintaining and reducing renal angiomyolipoma size, are 
      of great benefit to patients. IMPLICATIONS FOR PRACTICE: Treatment with 
      everolimus, an oral mTOR inhibitor, offers patients a noninvasive 
      pharmacotherapeutic treatment option. The NP, as a key member of the healthcare 
      team overseeing TSC patients, must be knowledgeable about the safety and efficacy 
      of mTOR inhibitors as their use in the patient population increases.
CI  - (c)2013 The Author(s) (c)2013 American Association of Nurse Practitioners.
FAU - Coombs, Elizabeth Jo
AU  - Coombs EJ
AD  - Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20131001
PL  - United States
TA  - J Am Assoc Nurse Pract
JT  - Journal of the American Association of Nurse Practitioners
JID - 101600770
RN  - 0 (Immunosuppressive Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
MH  - Angiomyolipoma/complications/*drug therapy
MH  - Everolimus
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Kidney Neoplasms/complications/*drug therapy
MH  - Sirolimus/*analogs & derivatives/therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
MH  - Tuberous Sclerosis/complications/*drug therapy
OTO - NOTNLM
OT  - Treatment guidelines
OT  - pharmacotherapy
OT  - renal
OT  - safety
OT  - treatment
EDAT- 2013/10/31 06:00
MHDA- 2015/04/10 06:00
CRDT- 2013/10/31 06:00
PHST- 2013/10/31 06:00 [entrez]
PHST- 2013/10/31 06:00 [pubmed]
PHST- 2015/04/10 06:00 [medline]
AID - 10.1002/2327-6924.12081 [doi]
PST - ppublish
SO  - J Am Assoc Nurse Pract. 2013 Nov;25(11):588-96. doi: 10.1002/2327-6924.12081. 
      Epub 2013 Oct 1.